|1.||Grigoriadis, D E: 1 article (10/2001)|
|2.||Mackay, K B: 1 article (10/2001)|
|3.||Bozigian, H: 1 article (10/2001)|
|4.||Foster, A C: 1 article (10/2001)|
|5.||Verge, G: 1 article (10/2001)|
|6.||Loddick, S A: 1 article (10/2001)|
10/01/2001 - "In this model of focal ischemia, significant reduction (P < 0.05) in both outcome measures was obtained when R121920 administration was delayed up to 1 hour after MCAO. "
10/01/2001 - "Neuroprotective effects of the CRF1 antagonist R121920 after permanent focal ischemia in the rat."
10/01/2001 - "In the intraluminal suture MCAO model, IV administration of R121920 (10 mg/kg) at the time of ischemia onset (and at multiple times thereafter) reduced both hemispheric infarct volume (by 34%, P < 0.001) and brain swelling (by 50%, P < 0.001) when assessed at 24 hours. "
|2.||Brain Ischemia (Cerebral Ischemia)
10/01/2001 - "The neuroprotective effects of a systemically active, highly selective, corticotropin-releasing factor-1 (CRF1) receptor antagonist, R121920 ((7-(dipropylamino)-2,5-dimethyl-3- [2-(dimethylamino)-5-pyridyl] pyrazolo [1,5-a] pyrimidine), was assessed in two rat models of permanent focal cerebral ischemia, where the middle cerebral artery (MCA) was occluded either through the subtemporal approach or using the intraluminal suture technique. "
|3.||Brain Edema (Cerebral Edema)
|1.||Adrenocorticotropic Hormone (ACTH)
|2.||CRF receptor type 1